PMEL Recombinant Antibody

$Paraformaldehyde-fixed, paraffin embedded Human melanoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with PMEL Monoclonal Antibody, Unconjugated(bsm-61122R) at 1:200 overnight at 4\u00b0C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining$

Paraformaldehyde-fixed, paraffin embedded Human melanoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with PMEL Monoclonal Antibody, Unconjugated(bsm-61122R) at 1:200 overnight at 4\u00b0C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining

$25 ug total protein per lane of various lysates (see on figure) probed with PMEL monoclonal antibody, unconjugated (bsm-61122R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with PMEL monoclonal antibody, unconjugated (bsm-61122R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
IHC-P
IHC-F
IF

Reactivity

Human

Overview
Catalog #	bsm-61122r
Product Name	PMEL Recombinant Antibody
Applications	WB, IHC-P, IHC-F, IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human PMEL
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6490
Swiss Prot	P40967
Subcellular location	Extracellular, Secreted
Synonyms	PMEL; ME20-M; Premelanosome protein; Silver locus protein homolog; PMEL17; SILV.
Background	Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IHC-F	1:100-500
IF